Table 3.

Cox proportional-hazards model for post-recurrence survival.

	Univariable		p value	Multivariable		p value
	HR	95% CI		HR	95% CI
TILs in primary tumours (≥10 vs. <10%)	1.77	0.83–3.80	0.14
TILs in metastatic tumours (≥10 vs. <10%)	0.45	0.19–1.05	0.065
TIL changes
No change	Ref	–	–	Ref	–	–
Decreased	2.94	1.41–6.13	0.004	1.36	0.50–3.66	0.55
Increased	0.12	0.016–0.88	0.0037	0.15	0.02–1.21	0.074
PD-L1 expression in primary tumours (positive vs. negative)	0.92	0.47–1.82	0.81
PD-L1 expression in metastatic tumours (positive vs. negative)	0.23	0.038–1.35	0.1
PD-L1 changes
No change	Ref	–	–
Decreased	1.85	0.79–4.33	0.16
Increased	0.25	0.035–1.88	0.18
Agea (≥65 vs. <65)	1.54	0.72–3.31	0.27
Tumour sizeb (≥pT2 vs. <pT2)	2.31	1.06–5.06	0.036	1.49	0.61–3.67	0.38
Nodal statusb (positive vs. negative)	1.75	0.85–3.60	0.13
Subtypec (TNBC vs. others)	2.08	1.004–4.30	0.049	1.77	0.74–4.23	0.2
HGb (3 vs. 1–2)	1.99	0.91–4.39	0.087
RFI (≥median vs. <median)	0.86	0.41–1.80	0.69
Visceral metastasisd (yes vs. no)	2.52	1.08–5.87	0.032	2.76	1.07–7.11	0.04
Adjuvant CT (yes vs. no)	4.26	1.90–9.54	<0.001	2.23	0.87–5.70	0.095
Adjuvant RT (yes vs. no)	0.97	0.47–2.01	0.95
Adjuvant HT (yes vs. no)	0.83	0.40–1.73	0.62

^aAt recurrence.

^bFor primary tumours.

^cFor metastatic tumours.

^dVisceral metastasis include liver, lung, brain metastasis.

CT chemotherapy, CI confidence interval, HR hazard ratio, HG histological grade, HT hormone therapy, RT radiotherapy, RFI recurrence-free interval, PD-L1 programmed death-ligand 1, TNBC triple-negative breast cancer, TIL stromal tumour-infiltrating lymphocyte.